Analyst about Bavarian: We have to wait patiently
Danske Bank analyst Thomas Bowers says there is a chance of new developments in a partnership between Bavarian Nordic and Bristol-Myers Squibb at the close of the year, while a new deal between the two both validates Bavarian’s platform and highlights the fierce competition seen in one particular immuno-oncology area.
BY STEFAN SINGH KAILAY
The thing to look out for in Bavarian Nordic’s quarterly report, published Wednesday, was not so much the financial numbers, but rather updates on the company’s pipeline activities.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Bavarian strikes historic Prostvac deal
For abonnenter
”It’s a top five deal”
For abonnenter
Bavarian Nordic strikes new deal with BMS
For abonnenter
